PTHS - Chromocell Therapeutics Corp

23
0.050   0.217%

Share volume: 18,667
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$22.95
0.05
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 43%
Liquidity 42%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.07%
1 Month
4.55%
3 Months
-5.54%
6 Months
-30.32%
1 Year
1,383.87%
2 Year
931.39%
Key data
Stock price
$23.00
P/E Ratio 
N/A
DAY RANGE
$22.90 - $23.20
EPS 
-$11.52
52 WEEK RANGE
$0.90 - $54.29
52 WEEK CHANGE
$1,578.83
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
3.356 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$19,396
AVERAGE 30 VOLUME 
$12,674
Company detail
CEO: Francis Knuettel II
Region: US
Website: chromocell.com
Employees: 0
IPO year: 2024
Issue type:
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Chromocell Therapeutics Corporation was incorporated in Delaware on March 19, 2021. Our principal executive offices are located at 4400 Route 9 South, Suite 1000, Freehold, NJ.

Recent news